Biotechnology
Transgenic mouse model reflects latest scientific understanding of disease – toxic oligomers of amyloid create cognitive deficit Excerpt from the Press Release: ORONTO, Ontario and CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as…
Read More
Phase 2/3 study initiated in collaboration with Eli Lilly and Company Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., March 02, 2022 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced the first patient has been dosed…
Read More
Following Discussion with the FDA, Karyopharm Plans to Initiate a New Placebo-Controlled Randomized Study of Selinexor in the Advanced or Recurrent Endometrial Cancer p53 Wild-Type Population to Support a Future sNDA Submission as the Current Topline Data from the SIENDO Study are Unlikely to Support an sNDA Approval Karyopharm is Encouraged by the SIENDO p53…
Read More
–Final data and potential for $25m milestone anticipated in H1 2023– Excerpt from the Press Release: SAN DIEGO, Feb. 24, 2022 /PRNewswire/ — Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today announced the completion of enrollment in the Phase 2 HERA clinical study…
Read More
Ability to serially monitor treatment response, identify key biomarkers and customize assay aids clinical research efforts to improve treatment for metastatic cancers involving brain and spinal cord Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Feb. 22, 2022– Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, highlighted the ability of its CNSide™ cerebrospinal…
Read More Excerpt from the Press Release: ROTTERDAM, Netherlands and SAN DIEGO, Feb. 24, 2022 /PRNewswire/ — Today, SkylineDx announced that their Merlin Test for melanoma patients would have been able to reduce over 59% of surgery-related complications by means of deselecting patients for surgery [2]. The commercially available Merlin Test identifies melanoma patients that can safely forgo a sentinel lymph node…
Read More
Excerpt from the Press Release: CARLSBAD, Calif.–(BUSINESS WIRE)–Ra Medical Systems, Inc. (NYSE American: RMED), a medical device company focused on developing its excimer laser system to treat vascular diseases, announces enrollment has reached 95 subjects in its pivotal clinical trial to evaluate the safety and effectiveness of the DABRA excimer laser system as an atherectomy…
Read More
The percentage of patients achieving clinical remission, clinical response, endoscopic improvement and corticosteroid-free remission was maintained through Week 142 Zeposia is the first and only oral sphingosine 1-phosphate (S1P) receptor modulator approved to treat patients with ulcerative colitis Excerpt from the Press Release: PRINCETON, N.J.–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) today announced interim results from the…
Read More
EDP-938 is Currently Being Evaluated in Phase 2 Studies in Pediatric Patients and Hematopoietic Stem Cell Transplant Recipients With RSV On Track to Report Topline Data from RSVP, a Phase 2b Study in Adults with Community-Acquired RSV Infection, in the Second Quarter of 2022 Excerpt from the Press Release: WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA),…
Read More
Evelo Biosciences Announces Dosing of First Patient in Phase 2 Trial of EDP1815 in Atopic Dermatitis
Excerpt from the Press Release: CAMBRIDGE, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) — Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that the first patient has been dosed in EDP1815-207, its Phase 2 randomized clinical trial of EDP1815…
Read More